Meeting
2013 ASCO Annual Meeting
CA184-156: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus placebo plus EP in patients (Pts) with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC).
Authors
Joachim Von Pawel
Asklepios Hospital Munich-Gauting, Munich, Germany
Joachim Von Pawel , Sang-We Kim , David R. Spigel , Christoph Zielinski , Maria Catherine Pietanza , Veerle de Pril , Marc S. Ballas , Martin Reck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01450761
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS7608)
DOI
10.1200/jco.2013.31.15_suppl.tps7608
Abstract #
TPS7608
Poster Bd #
31B
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A multicenter phase III randomized double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC).
First Author: Michael Seckl
Poster
2022 ASCO Annual Meeting
KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.
First Author: Jacob Sands
Poster
2021 ASCO Annual Meeting
KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.
First Author: Andreas Rimner
Poster
2017 ASCO Annual Meeting
A phase III study of rovalpituzumab tesirine maintenance therapy following first-line platinum-based chemotherapy in patients with extensive disease small cell lung cancer (ED SCLC).
First Author: Philip B. Komarnitsky